Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the role of cytoreductive surgery and Niraparib
maintenance in platinum-sensitive secondary recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Gynecologic Oncology Group
Collaborators:
Fudan University Shanghai Jiao Tong University School of Medicine Sun Yat-sen University Zhejiang Cancer Hospital